Osiris Therapeutics

Osiris Therapeutics, Inc. was founded in 1992 based on stem cell technology discovered by researchers at Case Western Reserve University led by Dr. Arnold Caplan. He recognized this technology had tremendous therapeutic potential.
Today, more than two decades after the journey began, Osiris continues to advance the science of cellular regenerative medicine to treat patients in need. Osiris Therapeutics, based in Columbia, Maryland, is the world leader in researching, developing and marketing regenerative medicine products. Having developed the world’s first approved stem cell drug, the company continues to advance its research and development in biotechnology by focusing on innovation in regenerative medicine – including bioengineering, stem cell research and viable tissue based products. Osiris has achieved commercial success with products in orthopaedics, sports medicine and wound care, including BIO4™, Cartiform® and Grafix®. Osiris, Grafix, and Cartiform are registered trademarks of Osiris Therapeutics, Inc. BIO4 is a trademark of Stryker Corporation (NYSE: SYK).

Columbia, US
Size (employees)
211 (est)
Osiris Therapeutics is headquartered in Columbia, US

Key People at Osiris Therapeutics

Lode Debrabandere

Lode Debrabandere

Prsident & CEO
Philip R. Jacoby

Philip R. Jacoby


Osiris Therapeutics Office Locations

Osiris Therapeutics has an office in Columbia
Columbia, US (HQ)
7015 Albert Einstein Drive

Osiris Therapeutics Metrics

Osiris Therapeutics Financial Metrics

Net income (2014)

($1.8 m)

Market capitalization (17-Mar-2017)

$110.6 m

Closing share price (17-Mar-2017)


Cash (31-Dec-2014)

$2.2 m
Osiris Therapeutics's current market capitalization is $110.6 m.
FY, 2013FY, 2014

Operating expense total

$20.5 m$45 m


($2.8 m)$1.7 m

Net Income

$41.6 m($1.8 m)
FY, 2013FY, 2014


$2.4 m$2.2 m

Accounts Receivable

$15.3 m$10 m


$355 k$650 k

Current Assets

$84.1 m$95.9 m


$1.9 m$2.1 m

Total Assets

$92.1 m$98.1 m

Accounts Payable

$4.8 m$8.9 m

Current Liabilities

$10.8 m$10.6 m

Additional Paid-in Capital

$282.7 m$287.5 m

Retained Earnings

($201.8 m)($203.5 m)

Total Equity

$80.9 m$84 m

Financial Leverage

1.1 x1.2 x
FY, 2013FY, 2014

Depreciation and Amortization

$587 k$940 k

Accounts Receivable

($4.7 m)($18 m)


($651 k)($9 m)

Accounts Payable

($2.8 m)($57 k)

Cash From Operating Activities

($13.3 m)($3.1 m)

Purchases of PP&E

($528 k)($1.1 m)

Cash From Investing Activities

$11.6 m$1.1 m

Cash From Financing Activities

$2.2 m$1.9 m

Income Taxes Paid

$539 k$619 k

Osiris Therapeutics Market Value History

Osiris Therapeutics Company Life

You may also be interested in